Precision BioSciences Doses First Patient in Phase 1/2 FUNCTION-DMD Study, but Timeline Slips

What happened

Precision BioSciences announced that it has dosed the first patient in its Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, marking the second wholly owned program to enter the clinic after IND clearance earlier in 2026. This milestone comes later than the company's guidance of late-Q1/early-Q2 2026, indicating a delay of several months in trial activation and first dosing. The start of dosing reduces regulatory and manufacturing risk for DMD but does not yet provide efficacy or safety data, which are expected later. The investment thesis previously rested on two near-term catalysts: HBV biopsy data in 1H26 and DMD first dosing; with DMD now initiated, attention shifts to the HBV mechanism update. Financial constraints remain, with restricted cash and limited issuance capacity, so the company still needs to manage its runway carefully.

Implication

Investors should recognize that DMD is now a clinical-stage asset, adding a second potential value driver, but the timeline slip suggests operational challenges that could also affect HBV. The company still must deliver HBV biopsy results to confirm the main near-term catalyst, and without that, the stock may stay range-bound. Financing constraints persist under the Baby Shelf Rule, and further delays could force more discounted equity raises. The DMD program now needs to generate initial multi-patient dystrophin data by year-end to maintain credibility. Overall, the risk/reward has improved with clinical initiation but remains speculative; position sizing should reflect that the balance sheet is not a strong backstop.

Thesis delta

The thesis has shifted from anticipating two binary catalysts to having one (DMD first dosing) realized, albeit later than guided. The delay tempers the bull scenario's assumption of rapid DMD execution, but the initiation of dosing reduces the probability of DMD failure due to regulatory or manufacturing issues. The core HBV thesis remains unchanged; the stock still hinges on 1H26 biopsy data to confirm mechanism.